# US 2019/0375849 A1 · Multi-specific binding proteins for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375849 A1
- Document ID: US20190375849A1
- Status: Published application
- Kind: A1
- Application number: 16/434,188
- Filed: 2019-06-07
- Published: 2019-12-12
- Earliest claimed: 2018-06-09
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Susanne Hipp; Paul Adam; Michael Dziegelewski; Rajkumar Ganesan; Nicholas Gorman; Priyanka Gupta; Justin Scheer; Vladimir H. Voynov
- Web page: https://patentgrep.com/patent/US20190375849A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/30: from tumour cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 1/14: Extraction; Separation; Purification
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases.

## Claims

### Claim 1

A protein comprising a first antigen binding unit specifically binding to DLL3 and a second antigen binding unit specifically binding to CD3, wherein said first antigen binding unit specifically binding to DLL3 is selected from the group consisting of i) to xviii):
i) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3);
ii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3);
is iii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3);
iv) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:19 (CDR1), SEQ ID NO:20 (CDR2) and SEQ ID NO:21 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:22 (CDR1), SEQ ID NO:23 (CDR2) and SEQ ID NO:24 (CDR3);
v) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:25 (CDR1), SEQ ID NO:26 (CDR2) and SEQ ID NO:27 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:28 (CDR1), SEQ ID NO:29 (CDR2) and SEQ ID NO:30 (CDR3);
vi) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:31 (CDR1), SEQ ID NO:32 (CDR2) and SEQ ID NO:33 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:34 (CDR1), SEQ ID NO:35 (CDR2) and SEQ ID NO:36 (CDR3);
vii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:133 (CDR1), SEQ ID NO:134 (CDR2) and SEQ ID NO:135 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:136 (CDR1), SEQ ID NO:137 (CDR2) and SEQ ID NO:138 (CDR3);
viii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:139 (CDR1), SEQ ID NO:140 (CDR2) and SEQ ID NO:141 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:142 (CDR1), SEQ ID NO:143 (CDR2) and SEQ ID NO:144 (CDR3);
ix) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:145 (CDR1), SEQ ID NO:146 (CDR2) and SEQ ID NO:147 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:148 (CDR1), SEQ ID NO:149 (CDR2) and SEQ ID NO:150 (CDR3);
x) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:151 (CDR1), SEQ ID NO:152 (CDR2) and SEQ ID NO:153 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:154 (CDR1), SEQ ID NO:155 (CDR2) and SEQ ID NO:156 (CDR3);
xi) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:157 (CDR1), SEQ ID NO:158 (CDR2) and SEQ ID NO:159 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:160 (CDR1), SEQ ID NO:161 (CDR2) and SEQ ID NO:162 (CDR3);
xii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:163 (CDR1), SEQ ID NO:164 (CDR2) and SEQ ID NO:165 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:166 (CDR1), SEQ ID NO:167 (CDR2) and SEQ ID NO:168 (CDR3);
xiii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:169 (CDR1), SEQ ID NO:170 (CDR2) and SEQ ID NO:171 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:172 (CDR1), SEQ ID NO:173 (CDR2) and SEQ ID NO:174 (CDR3);
xiv) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:175 (CDR1), SEQ ID NO:176 (CDR2) and SEQ ID NO:177 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:178 (CDR1), SEQ ID NO:179 (CDR2) and SEQ ID NO:180 (CDR3);
xv) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:181 (CDR1), SEQ ID NO:182 (CDR2) and SEQ ID NO:183 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:184 (CDR1), SEQ ID NO:185 (CDR2) and SEQ ID NO:186 (CDR3);
xvi) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:187 (CDR1), SEQ ID NO:188 (CDR2) and SEQ ID NO:189 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:190 (CDR1), SEQ ID NO:191 (CDR2) and SEQ ID NO:192 (CDR3);
xvii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:193 (CDR1), SEQ ID NO:194(CDR2) and SEQ ID NO:195 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:196 (CDR1), SEQ ID NO:197 (CDR2) and SEQ ID NO:198 (CDR3); and
xviii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:199 (CDR1), SEQ ID NO:200 (CDR2) and SEQ ID NO:201 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:202 (CDR1), SEQ ID NO:203 (CDR2) and SEQ ID NO:204 (CDR3).

### Claim 2 (depends on 1)

The protein of claim 1, wherein said first antigen binding unit specifically binding to DLL3 comprises a first light chain variable domain and a first heavy chain variable domain and is selected from the group consisting of i) to xviii):
i) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:38;
ii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequences of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:40;
iii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42;
iv) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:43 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44;
v) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:45 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46;
vi) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:48;
vii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:205 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:206;
viii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:207 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:208;
ix) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:209 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:210;
x) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:211 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:212;
xi) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:213 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:214;
xii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:215 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:216;
xiii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:217 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:218;
xiv) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:219 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:220;
xv) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:221 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:222;
xvi) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:223 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:224;
xvii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:225 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:226; and
xviii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:227 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:228.

### Claim 3 (depends on 1)

The protein of claim 1, wherein said second antigen binding unit specifically binding to CD3 is selected from the group consisting of i)-iii):
i) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3);
ii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); and
iii) an antigen binding unit comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:96 (CDR1), SEQ ID NO:97 (CDR2) and SEQ ID NO:98 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:99 (CDR1), SEQ ID NO:100 (CDR2) and SEQ ID NO:101 (CDR3).

### Claim 4 (depends on 1)

The protein of claim 1, wherein said second antigen binding unit specifically binding to CD3 comprises a second light chain variable domain and a second heavy chain variable domain selected from the group consisting of i) to iii):
i) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68;
ii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; and
iii) an antigen binding unit comprising a light chain variable domain comprising the amino acid sequence of SEQ ID NO:102 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:103.

### Claim 5 (depends on 1)

The protein of claim 1, wherein
i) said first antigen binding unit specifically binding to DLL3 comprises from its N- to C-terminus a first light chain variable domain, a first light chain constant domain, a first peptide linker, a first heavy chain variable domain and a first heavy chain constant CH1 domain; and
ii) said second antigen binding unit specifically binding to CD3 comprises from its N- to C-terminus a second light chain variable domain, a second light chain constant domain, a second peptide linker, a second heavy chain variable domain and a second heavy chain constant CH1 domain.

### Claim 6 (depends on 5)

The protein of claim 5, wherein said first and/or second peptide linker comprises 26 to 42 amino acids, 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids.

### Claim 7 (depends on 5)

The protein of claim 5, wherein said first linker and/or second linker is a Gly-Ser linker, selected from the group consisting of the amino acid sequence of SEQ ID NO:89, and an amino acid sequence wherein said first and second peptide linker comprise the same sequence.

### Claim 8 (depends on 5)

The protein of claim 5, further comprising a first and a second Fc domain, said first Fc domain covalently linked to said first antigen binding unit, and a said second Fc domain covalently linked to said second antigen binding unit.

### Claim 9 (depends on 8)

The protein of claim 8, wherein
i) said first Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said second Fc domain comprises a threonine (T) at position 407 [Y4071], or
ii) said first Fc domain comprises a tryptophan (W) at position 366 [T366W], and said second Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or
iii) said second Fc domain comprises a tyrosine (Y) at position 366 [T366Y], and said first Fc domain comprises a threonine (T) at position 407 [Y4071], or
iv) said second Fc domain comprises a tryptophan (W) at position 366 [T366W], and said first Fc domain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V],
wherein said first or said second Fc domain optionally further comprises an arginine at position 435 [H435R] and a phenylalanine at position 436 [Y436F].

### Claim 10 (depends on 9)

The protein of claim 9, wherein said first and/or said second Fc domain further comprises an alanine at position 234[L234A] and at position 235 [L235A].

### Claim 11 (depends on 5)

The protein of claim 5, wherein the first light chain constant domain and the second light chain constant domain comprise a human kappa or lambda domain.

### Claim 12

A protein comprising a first polypeptide chain specifically binding to DLL3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, SEQ ID NO:241, SEQ ID NO; 242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO: 245, SEQ ID NO: 246, SEQ ID NO: 247, SEQ ID NO: 248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, and SEQ ID NO: 252 and a second polypeptide chain specifically binding to CD3 comprising the amino acid sequence of SEQ ID NO:79, SEQ ID NO:80 or SEQ ID NO:105.

### Claim 13 (depends on 1)

An isolated nucleic acid molecule encoding the first antigen binding unit and/or the second antigen binding unit of a protein of claim 1, optionally further encoding a first and/or a second Fc domain.

### Claim 14 (depends on 12)

An isolated nucleic acid molecule encoding the first and/or the second polypeptide chain of claim 12.

### Claim 15 (depends on 13)

An expression vector comprising the nucleic acid molecule of claim 13.

### Claim 16 (depends on 15)

A host cell transfected with the expression vector of claim 15.

### Claim 17 (depends on 1)

A method of manufacturing a protein of claim 1, comprising
i) cultivating a host cell transfected with an expression vector encoding the first antigen binding unit and/or the second antigen binding unit of a protein under conditions allowing expression of the protein of claim 1; and,
ii) recovering the protein; and optionally
iii) further purifying and/or modifying and/or formulating the protein.

### Claim 18

A protein comprising a first polypeptide chain specifically binding to DLL3 and a second polypeptide chain specifically binding to CD3, wherein said first polypeptide chain comprises a first light chain, a first linker, and a first heavy chain and said second polypeptide chain comprises a second light chain, a second linker, and a second heavy chain, wherein the C-terminus of said first light chain is covalently linked to the N-terminus of said first heavy chain via said first peptide linker and wherein the C-terminus of said second light chain is covalently linked to the N-terminus of said second heavy chain via said second peptide linker.

### Claim 19 (depends on 18)

The protein of claim 18, wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and heavy chain variable domain comprising CDR sequences selected from the group consisting of i) to xviii):
i) light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and a heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3);
ii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3);
iii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3);
iv) light chain CDRs comprising the amino acid sequences of SEQ ID NO:19 (CDR1), SEQ ID NO:20 (CDR2) and SEQ ID NO:21 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:22 (CDR1), SEQ ID NO:23 (CDR2) and SEQ ID NO:24 (CDR3);
v) light chain CDRs comprising the amino acid sequences of SEQ ID NO:25 (CDR1), SEQ ID NO:26 (CDR2) and SEQ ID NO:27 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:28 (CDR1), SEQ ID NO:29 (CDR2) and SEQ ID NO:30 (CDR3);
vi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:31 (CDR1), SEQ ID NO:32 (CDR2) and SEQ ID NO:33 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:34 (CDR1), SEQ ID NO:35 (CDR2) and SEQ ID NO:36 (CDR3);
vii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:133 (CDR1), SEQ ID NO:134 (CDR2) and SEQ ID NO:135 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:136 (CDR1), SEQ ID NO:137 (CDR2) and SEQ ID NO:138 (CDR3);
viii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:139 (CDR1), SEQ ID NO:140 (CDR2) and SEQ ID NO:141 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:142 (CDR1), SEQ ID NO:143 (CDR2) and SEQ ID NO:144 (CDR3);
ix) light chain CDRs comprising the amino acid sequences of SEQ ID NO:145 (CDR1), SEQ ID NO:146 (CDR2) and SEQ ID NO:147 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:148 (CDR1), SEQ ID NO:149 (CDR2) and SEQ ID NO:150 (CDR3);
x) light chain CDRs comprising the amino acid sequences of SEQ ID NO:151 (CDR1), SEQ ID NO:152 (CDR2) and SEQ ID NO:153 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:154 (CDR1), SEQ ID NO:155 (CDR2) and SEQ ID NO:156 (CDR3);
xi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:157 (CDR1), SEQ ID NO:158 (CDR2) and SEQ ID NO:159 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:160 (CDR1), SEQ ID NO:161 (CDR2) and SEQ ID NO:162 (CDR3);
xii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:163 (CDR1), SEQ ID NO:164 (CDR2) and SEQ ID NO:165 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:166 (CDR1), SEQ ID NO:167 (CDR2) and SEQ ID NO:168 (CDR3);
xiii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:169 (CDR1), SEQ ID NO:170 (CDR2) and SEQ ID NO:171 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:172 (CDR1), SEQ ID NO:173 (CDR2) and SEQ ID NO:174 (CDR3);
light chain CDRs comprising the amino acid sequences of SEQ ID NO:175 (CDR1), SEQ ID NO:176 (CDR2) and SEQ ID NO:177 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:178 (CDR1), SEQ ID NO:179 (CDR2) and SEQ ID NO:180 (CDR3);
xiv) light chain CDRs comprising the amino acid sequences of SEQ ID NO:181 (CDR1), SEQ ID NO:182 (CDR2) and SEQ ID NO:183 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:184 (CDR1), SEQ ID NO:185 (CDR2) and SEQ ID NO:186 (CDR3);
xv) light chain CDRs comprising the amino acid sequences of SEQ ID NO:187 (CDR1), SEQ ID NO:188 (CDR2) and SEQ ID NO:189 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:190 (CDR1), SEQ ID NO:191 (CDR2) and SEQ ID NO:192 (CDR3);
xvi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:193 (CDR1), SEQ ID NO:194(CDR2) and SEQ ID NO:195 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:196 (CDR1), SEQ ID NO:197 (CDR2) and SEQ ID NO:198 (CDR3); and
xvii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:199 (CDR1), SEQ ID NO:200 (CDR2) and SEQ ID NO:201 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:202 (CDR1), SEQ ID NO:203 (CDR2) and SEQ ID NO:204 (CDR3).

### Claim 20 (depends on 18)

The protein of claim 18, wherein said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and heavy chain variable domain comprising CDR sequences selected from the group consisting of i) to iii):
i) light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3);
ii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:61 (CDR1), SEQ ID NO:62 (CDR2) and SEQ ID NO:63 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:64 (CDR1), SEQ ID NO:65 (CDR2) and SEQ ID NO:66 (CDR3); and
iii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:96 (CDR1), SEQ ID NO:97 (CDR2) and SEQ ID NO:98 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:99 (CDR1), SEQ ID NO:100 (CDR2) and SEQ ID NO:101 (CDR3).

### Claim 21 (depends on 18)

The protein of claim 18, wherein said first polypeptide chain specifically binding to DLL3 comprises a light chain variable domain and a heavy chain variable domain selected from the group consisting of i) to xviii):
i) a light chain variable domain comprising the amino acid sequences of SEQ ID NO:37 and heavy chain variable domain comprising the amino acid sequences of SEQ ID NO:38;
ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:39 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:40;
iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:41 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:42;
iv) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:43 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:44;
v) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:45 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:46;
vi) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:47 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:48;
vii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:205 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:206;
viii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:207 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:208;
ix) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:209 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:210;
x) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:211 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:212;
xi) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:213 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:214;
xii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:215 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:216;
xiii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:217 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:218;
xiv) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:219 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:220;
xv) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:221 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:222;
xvi) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:223 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:224;
xvii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:225 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:226; and
xviii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:227 and heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:228.

### Claim 22 (depends on 19)

The protein of claim 19, wherein said second polypeptide chain specifically binding to CD3 comprises a light chain variable domain and a heavy chain variable domain selected from the group consisting of i)-iii):
i) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:67 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:68;
ii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:69 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:70; and
iii) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:102 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:103.

### Claim 23 (depends on 18)

The protein of claim 18, wherein said first and/or second peptide linker comprises 26 to 42 amino acids, 30 to 40 amino acids, 34 to 40 amino acids, or 36 to 39 amino acids.

### Claim 24 (depends on 23)

The protein of claim 23, wherein said first linker and/or second linker is a Gly-Ser linker, is selected from the group consisting of the amino acid sequence of SEQ ID NO:89, and an amino acid sequence wherein said first and second peptide linker comprise the same sequence.

### Claim 25 (depends on 18)

The protein of claim 18, wherein
i) said first heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and said second heavy chain comprises a threonine (T) at position 407 [Y407T], or
ii) said first heavy chain comprises a tryptophan (W) at position 366 [T366W], and said second heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V], or
iii) said second heavy chain comprises a tyrosine (Y) at position 366 [T366Y], and said first heavy chain comprises a threonine (T) at position 407 [Y4071], or
iv) said second heavy chain comprises a tryptophan (W) at position 366 [T366W], and said first heavy chain comprises a serine (S) at position 366 [T366S], an alanine (A) at position 368 [L368A] and a valine (V) at position 407 [Y407V],
wherein said first or said second heavy chain optionally further comprises an arginine at position 435 [H435R] and a phenylalanine at position 436 [Y436F].

### Claim 26 (depends on 25)

The protein of claim 25, wherein said first and/or said second heavy chain further comprises an alanine at position 234[L234A] and at position 235 [L235A].

### Claim 27 (depends on 18)

The protein of claim 18, wherein said first light chain and said second light chain comprise a human kappa or lambda domain.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 1)

A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of the protein of claim 1.

### Claim 30 (depends on 28)

A method of treating cancer comprising administering to a patient in need thereof of a therapeutically effective amount of the pharmaceutical composition of claim 28.

### Claim 31 (depends on 29)

The method of claim 29, wherein the cancer is a DLL3 expressing tumor, SCLC, glioblastoma, or a DLL3 expressing neuroendocrine tumor.

### Claim 32 (depends on 29)

The method of claim 29, wherein said protein is used in combination with a chemotherapeutic agent, a therapeutically active compound that inhibits angiogenesis, a signal transduction pathway inhibitor, an EGFR inhibitor, an immune modulator, an immune checkpoint inhibitor, or a hormonal therapy agent.

### Claim 33 (depends on 32)

The method of claim 32, wherein said protein is in combination with an immune checkpoint inhibitor, an anti-PD-1 antibody, or an anti-PD-L1 antibody.

### Claim 34 (depends on 33)

The method of claim 33, wherein the anti-PD-1 antibody is selected from the group consisting of PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5.

### Claim 35

An anti-DLL3 antibody molecule comprising
i) light chain CDRs comprising the amino acid sequences of SEQ ID NO:1 (CDR1), SEQ ID NO:2 (CDR2) and SEQ ID NO:3 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:4 (CDR1), SEQ ID NO:5 (CDR2) and SEQ ID NO:6 (CDR3); or
ii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:7 (CDR1), SEQ ID NO:8 (CDR2) and SEQ ID NO:9 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:10 (CDR1), SEQ ID NO:11 (CDR2) and SEQ ID NO:12 (CDR3); or
iii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3); or
iv) light chain CDRs comprising the amino acid sequences of SEQ ID NO:19 (CDR1), SEQ ID NO:20 (CDR2) and SEQ ID NO:21 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:22 (CDR1), SEQ ID NO:23 (CDR2) and SEQ ID NO:24 (CDR3); or
v) light chain CDRs comprising the amino acid sequences of SEQ ID NO:25 (CDR1), SEQ ID NO:26 (CDR2) and SEQ ID NO:27 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:28 (CDR1), SEQ ID NO:29 (CDR2) and SEQ ID NO:30 (CDR3); or
vi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:31 (CDR1), SEQ ID NO:32 (CDR2) and SEQ ID NO:33 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:34 (CDR1), SEQ ID NO:35 (CDR2) and SEQ ID NO:36 (CDR3); or
vii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:133 (CDR1), SEQ ID NO:134 (CDR2) and SEQ ID NO:135 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:136 (CDR1), SEQ ID NO:137 (CDR2) and SEQ ID NO:138 (CDR3); or
viii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:139 (CDR1), SEQ ID NO:140 (CDR2) and SEQ ID NO:141 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:142 (CDR1), SEQ ID NO:143 (CDR2) and SEQ ID NO:144 (CDR3); or
ix) light chain CDRs comprising the amino acid sequences of SEQ ID NO:145 (CDR1), SEQ ID NO:146 (CDR2) and SEQ ID NO:147 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:148 (CDR1), SEQ ID NO:149 (CDR2) and SEQ ID NO:150 (CDR3); or
x) light chain CDRs comprising the amino acid sequences of SEQ ID NO:151 (CDR1), SEQ ID NO:152 (CDR2) and SEQ ID NO:153 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:154 (CDR1), SEQ ID NO:155 (CDR2) and SEQ ID NO:156 (CDR3); or
xi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:157 (CDR1), SEQ ID NO:158 (CDR2) and SEQ ID NO:159 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:160 (CDR1), SEQ ID NO:161 (CDR2) and SEQ ID NO:162 (CDR3); or
xii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:163 (CDR1), SEQ ID NO:164 (CDR2) and SEQ ID NO:165 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:166 (CDR1), SEQ ID NO:167 (CDR2) and SEQ ID NO:168 (CDR3); or
xiii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:169 (CDR1), SEQ ID NO:170 (CDR2) and SEQ ID NO:171 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:172 (CDR1), SEQ ID NO:173 (CDR2) and SEQ ID NO:174 (CDR3); or
xiv) comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:175 (CDR1), SEQ ID NO:176 (CDR2) and SEQ ID NO:177 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:178 (CDR1), SEQ ID NO:179 (CDR2) and SEQ ID NO:180 (CDR3); or
xv) light chain CDRs comprising the amino acid sequences of SEQ ID NO:181 (CDR1), SEQ ID NO:182 (CDR2) and SEQ ID NO:183 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:184 (CDR1), SEQ ID NO:185 (CDR2) and SEQ ID NO:186 (CDR3); or
xvi) light chain CDRs comprising the amino acid sequences of SEQ ID NO:187 (CDR1), SEQ ID NO:188 (CDR2) and SEQ ID NO:189 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:190 (CDR1), SEQ ID NO:191 (CDR2) and SEQ ID NO:192 (CDR3); or
xvii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:193 (CDR1), SEQ ID NO:194(CDR2) and SEQ ID NO:195 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:196 (CDR1), SEQ ID NO:197 (CDR2) and SEQ ID NO:198 (CDR3); or
xviii) light chain CDRs comprising the amino acid sequences of SEQ ID NO:199 (CDR1), SEQ ID NO:200 (CDR2) and SEQ ID NO:201 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:202 (CDR1), SEQ ID NO:203 (CDR2) and SEQ ID NO:204 (CDR3).

### Claim 36 (depends on 35)

The anti-DLL3 antibody molecule of claim 35, wherein said antibody molecule is a monoclonal, a chimeric, a humanized or a human antibody molecule.

### Claim 37 (depends on 35)

The anti-DLL3 antibody molecule of claim 35, wherein said antibody molecule is a Fab, F(ab′)2, Fab′, Fv or scFv.

### Claim 38 (depends on 35)

The anti-DLL3 antibody molecule of claim 35, wherein the heavy chain constant region is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions.

### Claim 39 (depends on 35)

The anti-DLL3 antibody molecule of claim 35, wherein the light chain constant region is kappa or lambda.

### Claim 40 (depends on 37)

A method of detecting DLL3 in a biological sample comprising
(a) contacting the sample with an anti-DLL3 antibody of claim 37;
(b) permitting formation of antibody-antigen complexes in the sample; and
(c) detecting the anti-DLL3 antibody.

### Claim 41 (depends on 40)

The method of claim 40, wherein the anti-DLL3 antibody is detected by a detectable signal, wherein said signal is detected by immunocytochemistry (ICC), immunohistochemistry (IHC), Western Blotting, Flow cytometry and/or ELISA.

### Claim 42 (depends on 40)

The method of claim 40, wherein the biological sample is a tissue sample, a fixed tissue sample, and/or a formalin-fixed and paraffin-embedded tissue sample.

### Claim 43 (depends on 42)

The method of claim 42, wherein the anti-DLL3 antibody is detected by IHC.

### Claim 44 (depends on 40)

The method of claim 40, wherein the tissue sample is a tumor tissue sample, and/or a tumor tissue sample isolated from a tumor selected from the group consisting of SCLC, LCNEC, glioma, glioblastoma, melanoma, or other neuroendocrine tumors.

### Claim 45 (depends on 35)

A kit for detecting DLL3 comprising an antibody of claim 35, and instructions for use.
